JAN101 Showed Statistically Significant
Reduction in Pain and Improvement in Nerve Conduction Velocity in
Prior Phase II study.
LAS
VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), a biopharmaceutical company specializing in
developing non-addicting pain killers and treatments for underlying
causes of pain, will present prior data on Jan101's randomized
double blind placebo-controlled trial in diabetic neuropathy
patients.
Dr. Amol Soin, Chief Medical Officer of JanOne, will
present the results and noted that "This data shows that Jan101 may
provide a non-opioid solution to treat diabetic neuropathy pain,
but what was also quite exciting was that we saw improvement in
nerve conduction velocity which may indicate that Jan101 may
actually help the disease process by potentially improving nerve
function. If proven further, this could be game changing for
patients."
The Ohio Society of Interventional Pain Physicians annual
meeting is a large regional pain management meeting from
August 17 – 20th that
draws attendance from physicians across the US. Diabetic neuropathy
is an often-debilitating condition that is on the rise in the
USA characterized by burning pain
and numbness typically in the extremities. There currently are few
to no effective treatments that show improvement in nerve
conduction velocity.
"We look forward to presenting our data and telling the story of
Jan101 which we feel may provide great therapeutic benefit to
patients who suffer from diabetic neuropathy," said Tony Isaac, JanOne's CEO.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN101 will treat PAD, that JAN 123
will treat CRPS, the timing of the commencement of clinical trials,
that the FDA will permit approval through a 505(b)(2) pathway for
JAN 123, that upon approval JAN101 will immediately disrupt the PAD
market, and other statements, including words such as "continue",
"expect", "intend", "will", "hope" "should", "would", "may",
"potential" and other similar expressions. Such statements
reflect JanOne's current view with respect to future events,
are subject to risks and uncertainties, and are necessarily based
upon a number of estimates and assumptions that, while considered
reasonable by JanOne, are inherently subject to significant
business, economic, competitive, political and social uncertainties
and contingencies. Many factors could cause JanOne's actual
results, performance or achievements to be materially different
from any future results, performance or achievements described in
this press release. Such factors could include, among others, those
detailed in the Company's periodic reports filed with the
Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize,
or should the assumptions set out in the section entitled "Risk
Factors" in JanOne's filings with the SEC underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and JanOne
does not intend, and does not assume any obligation, to update
these forward-looking statements, except as required by law. JanOne
cannot assure that such statements will prove to be accurate as
actual results and future events could differ materially from those
anticipated in such statements. Individuals are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance
on forward-looking statements due to the inherent uncertainty
therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative,
actionable solutions that it believes can help create an end to the
opioid crisis. JanOne is dedicated to funding resources toward
innovation, technology and education to find a key resolution to
the national opioid epidemic, which is one of the deadliest and
widespread in the country's history. The company recently sold its
legacy business – ARCA Recycling – under its current brand name.
JanOne's subsidiary, ARCA Recycling, recycled household appliances
by providing turnkey recycling and replacement services for
utilities and other sponsors of energy efficiency programs.
Please visit www.janone.com for additional information.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-to-present-prior-phase-ii-data-on-diabetic-neuropathy-at-the-ohio-society-of-interventional-pain-physicians-annual-meeting-301904684.html
SOURCE JanOne Inc.